Monday, September 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Financial Performance of Jasper Therapeutics for the Year Ending December 31 2023

Elaine Mendonca by Elaine Mendonca
March 4, 2024
in Breaking News
0
Biotechnology Markets and money
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Jasper Therapeutics recorded a net loss of $16.6 million and $64.5 million for the three months and the year ended on December 31, 2023, respectively. The basic and diluted net loss per share for common stockholders were $1.50 and $6.18 during the same periods. The company’s cash and cash equivalents totaled $86.9 million as of December 31, 2023. Research and development expenses for the year ended December 31, 2023, amounted to $51.8 million, with stock-based compensation expenses of $1.6 million included. General and administrative expenses for the same period were $17.1 million, with stock-based compensation expenses of $3.6 million.

—

On March 4, 2024, Jasper Therapeutics reported a net loss of $16.6 million and $64.5 million for the three months and the year ending on December 31, 2023. The basic and diluted net loss per share attributable to common stockholders were $1.50 and $6.18 for the same periods. Moreover, the company’s cash and cash equivalents as of December 31, 2023, were reported at $86.9 million. Research and development expenses for the year ending December 31, 2023, were $51.8 million, which included stock-based compensation expenses of $1.6 million. General and administrative expenses for the same period were $17.1 million, with stock-based compensation expenses of $3.6 million.

[bs_slider_forecast ticker=”JSPR”]

JSPR Stock Shows Strong Performance with Positive Price Momentum in Pre-Market Trading

On March 4, 2024, JSPR stock had a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the stock. The price of JSPR shares had increased by $0.83 since the market last closed, representing a 3.91% rise. In pre-market trading on March 4, the stock had risen by an additional $0.67. This strong performance suggests that investors have confidence in JSPR and are optimistic about its future prospects. It is important for investors to continue monitoring JSPR stock and staying informed about any news or developments that may impact its performance.

Currently Playing

JSPR Stock Performance Review: Mixed Data Leaves Investors Uncertain on March 4, 2024

On March 4, 2024, investors in JSPR stock may have been feeling uncertain about the company’s financial performance based on the available data. According to CNN Money, JSPR’s total revenue information was currently unavailable, leaving investors without a key indicator of the company’s financial health.

The data that was available showed that JSPR had experienced a decrease in net income over the past year. The company reported a net income of -$37.69 million for the past year, which was a 23.0% decrease from the previous year. In the most recent quarter, JSPR reported a net income of -$17.54 million, representing a 9.1% decrease from the previous quarter.

Despite the decrease in net income, there was a glimmer of hope for investors in the form of earnings per share (EPS) data. JSPR reported an EPS of -$10.33 for the past year, which actually represented a 61.59% increase from the previous year. However, in the most recent quarter, the company reported an EPS of -$1.60, which was an 8.61% decrease from the previous quarter.

Overall, the mixed performance data for JSPR on March 4, 2024, may have left investors feeling uncertain about the company’s future prospects. While the increase in EPS over the past year was a positive sign, the decreases in net income over the same period could be cause for concern. Without more information on the company’s total revenue, investors may have been left wondering about JSPR’s overall financial health and future performance.

[stock_market_chart symbol=”JSPR” range=”3mo” interval=”1d” settings='{“primaryChartType”:”smoothedLine”,”secondaryChartType”:”column”,”width”:”100%”,”height”:”500px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:14,”color”:”#383838″,”primaryLineColor”:”#5679ff”,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#5679ff”,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#020202″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#e8e8e8″,”scrollbarSelectedBackgroundColor”:”#f7f7f7″,”scrollbarGraphFillColor”:”#435dc2″,”scrollbarSelectedGraphFillColor”:”#92a8fc”,”primaryLineThickness”:2,”secondaryLineThickness”:1,”gridThickness”:1,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”searchMode”:”search”,”mouseWheelZoomEnabled”:false,”cursorEnabled”:true,”exportEnabled”:true,”scrollbarEnabled”:true,”legendEnabled”:true,”periods”:”1D,1M,YTD,ALL”,”defaultPeriod”:”1M”}’]

Tags: JSPR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ projections

Financial Analysts Bullish on Li Auto Stock

Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Lyfts Stock Rises After Upgrade from RBC Capital

Pharmaceutical Markets and money

Analyst Raghuram Selvaraju Reiterates Buy Rating for BridgeBio Pharma with 47 Price Target

Recommended

Technology Quantum computing Market Capitalization

Digimarc Corporation Unveils NextGeneration Digital Watermarks

2 years ago
Quanta Services Stock

Infrastructure Giant Quanta Services Powers Up With Strategic Acquisition

4 days ago
MO stock news

RTW Investments LP Reduces Stake in Illumina, Inc. (NASDAQ:ILMN) as Company Exceeds Earnings Expectations and Reports Revenue Growth

2 years ago
DVY stock news

Stonnington Group LLC Buys Stake in Floor & Decor Holdings, Inc.: Implications for Future Growth?

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Leadership Crisis at Nestlé Sparks Investor Concerns

Standex Shares Plunge Amid Technical Warnings and Insider Selling

Navigating Credit Headwinds: Synchrony’s Strategic Expansion Amid Sector Challenges

Tech Sector Surge: AI and Cloud Computing Fuel Vanguard ETF’s Record Run

Gladstone Capital Executes Strategic Debt Refinancing and Rewards Shareholders

Executive Share Sales and Management Shifts Raise Questions at Repay Holdings

Trending

Tutor Perini Stock
Industrial

Insider Sales at Tutor Perini Coincide with Stock Peak

by Andreas Sommer
September 22, 2025
0

Shares of construction giant Tutor Perini Corporation have surged to a new annual high, a move immediately...

Ubiquiti Stock

Ubiquiti Shares Reach New Heights on Product Expansion Momentum

September 22, 2025
BioNTech Stock

BioNTech’s Strategic Pivot: From Pandemic Success to Oncology Innovation

September 22, 2025
Nestle Stock

Leadership Crisis at Nestlé Sparks Investor Concerns

September 22, 2025
Standex Stock

Standex Shares Plunge Amid Technical Warnings and Insider Selling

September 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Insider Sales at Tutor Perini Coincide with Stock Peak
  • Ubiquiti Shares Reach New Heights on Product Expansion Momentum
  • BioNTech’s Strategic Pivot: From Pandemic Success to Oncology Innovation

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com